Modality
ASO
MOA
Anti-Aβ
Target
SHP2
Pathway
Complement
Obesity
Development Pipeline
Preclinical
Jan 2020
PreclinicalCurrent
NCT03089719
650 pts·Obesity
2020-01→TBD·Terminated
650 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2020
Preclinical
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03089719 | Preclinical | Obesity | Terminated | 650 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP |